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Objective: To observe the therapeutic effects of midnight-noon ebb-flow method of selecting acupoints 
(MNEFMSA) for acute ischemic cerebrovascular diseases (AICD) and its influence on hemorrheology and 
on the levels of interleukin-6 (IL-6), thromboxane B2 (TXB2) and 6-keto-prostaglandin F1α (6-keto-PGF1α). 
Methods: The 90 cases were randomly divided into 3 groups, each consisting of 30 cases. The drug group 
was treated mainly by routine medication; in addition to medication, the affected-channel group was treated 
by acupuncture at points along the course of the affected channel, and the MNEFMSA group was treated by 
MNEFMSA. Results: The total effective rate of MNEFMSA group, affected-channel group and drug group 
was 96.67%, 90% and 73.33% respectively. The total effective rate of MNEFMSA group was obviously 
superior to that of the drug group (P<0.01), and cure rate and marked improvement rate were obviously 
superior to those of the drug group and the affected-channel group (P<0.05 or P<0.01). After treatment, the 
three groups all got improvements in the hemorheological indexes, of which MNEFMSA group got marked 
improvements in the whole blood viscosity and erythrocyte deformability rate, significantly different from 
the other two groups (P<0.05). At the early stage of treatment and after treatment, the three groups all had 
IL-6, TXB2 and 6-keto-PGF1α obviously improved (P<0.05 or P<0.01), of which MNEFMSA group got 
obvious improvement in 6-keto-PGF1α and IL-6 ever since the early stage of the treatment (P<0.05). 
Conclusions: In the treatment of acute ischemic cerebrovascular diseases, MNEFMSA can markedly raise 
the clinical therapeutic effects by improving the hemorheological indexes, lowering the level of IL-6, and 
restoring the dynamic equilibrium between TXB2 and 6-keto-PGF1α, so as to promote the recovery of 
cerebral nervous function.  
Acute ischemic cerebrovascular diseases are 
frequently encountered in clinic. Data show that their 
onset tend to have diurnal rhythm difference, 1-3
which is related with the human ‘biological clock’. 
Midnight-noon ebb-flow method of selecting 
acupoints (MNEFMSA) is adopted in the treatment 
here, and the comparison with control groups is 
conducted to observe the clinical effect and the 
influence on hemorrheology, interleukin-6 (IL-6), 
thromboxane B2 (TXB2) and 6-keto-prostaglandin F1α
(6-keto-PGF1α). The report is as follows.  
CLINICAL MATERIAL 
The 90 cases in this series were all inpatients in the 
Second Hospital of Lanzhou University in the period 
from May 1999 to August 2002. Of them, there were 
56 males and 34 females, ranging in age from 41 to 
82 years, with a mean of 57.8 years. All the patients 
got the acute onset and were hospitalized within 2 
hours to 3 days after the attack. They were all 
diagnosed by CT and MRI as having acute ischemic 
cerebrovascular disease (cerebral thrombosis, 
cerebral infarction), with the diseases of heart, liver, 
kidney, lung, endocrine and metabolism excluded. 
The damage of nervous function was evaluated based 
on the Evaluation Criteria for the Clinical Damage 
of Nervous Function of Cerebral Apoplexy Patient
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adopted at the Fourth National Academic Symposium 
on Cerebrovascular Diseases in 1995. 4 According to 
the TCM differentiation and based on the Criteria for 
TCM Diagnosis and Therapeutic Effect, 5 the patients 
were differentiated into 5 syndrome patterns: hyper- 
activity of liver-yang (14 cases), obstruction of 
collaterals by wind-phlegm (19 cases), phlegm-heat 
and excess of fu-organs (12 cases), qi-insufficiency 
and blood stasis (27 cases), and yin-deficiency with 
stirring of wind (18 cases). With the order of 
hospitalization, the drug group, affected-channel 
group and MNEFMSA group were formed randomly, 
each consisting of 30 cases. There were no significant 
statistical differences in sex, age, damage of nervous 
function and TCM syndromes among the three 
groups (P>0.05).  
METHODS 
All the patients were given the routine drug treatment 
with intravenous drip of dextran 40 added with 
compound salvia injection, and energy mixture added 
with citicoline. Patients accompanied with acute 
encephaledema were given mannitol by intravenous 
drip. The patients of drug group received only routine 
drug treatment. Based on routine drug treatment, the 
affected-channel group was given acupuncture, with 
the points selected from the affected channels, such 
as on the upper limb Jianyu (LI 15), Quchi (LI 11), 
Shousanli (LI 10), Waiguan (TE 5), Hegu (LI 4) and 
Houxi (SI 3), and on the lower limb Huantiao (GB 
30), Futu (ST 32), Zusanli (ST 36), Yanglingquan 
(GB 34), Xuanzhong (GB 39), Sanyinjiao (SP 6) and 
Kunlun (BL 60). For patients with hyperactivity of 
liver-yang, Baihui (GV 20) and Taichong (LR 3) 
were added; for obstruction of collaterals by 
wind-phlegm, Fengchi (GB 20) and Fenglong (ST 40) 
were added; for phlegm-heat and excess of fu-organs, 
Dazhui (GV 14) and Tianshu (ST 25) were added; for 
qi-insufficiency and blood stasis, Zhongwan (CV 12) 
and Qihai (CV 6) were added; and for yin-deficiency 
with stirring of wind, Neiguan (PC 6) and Taixi (KI 3) 
were added. Each day, 4 – 5 points of the upper limb 
and 4 – 5 points of the lower limb were punctured 
with the uniform reinforcing-reducing method and 
the needles were retained for 30 min. In addition to 
the routine drug treatment, based on Xu’s 
MNEFMSA recorded in Zheng Kuishan’s Midnight 
-Noon Ebb-Flow and the Eight Techniques of 
Magicturtle (ᄤज⌕⊼Ϣ♉啳ܿ⊩), 6 MNEFMSA 
group was treated with selecting points and 
administering acupuncture according to time and date 
of midnight-noon ebb-flow in rhythm. The selected 
points were taken as the main points, which were 
needled first, combined with 1 – 2 adjunct points 
selected from the upper and lower limbs or the trunk, 
which were needled later. The needle manipulation 
and the duration of needle retaining were the same as 
those of the affected-channel group. The three groups 
all began their treatments at the period from 7 am to 9 
am. Fifteen treatments constituted a course, with 3 – 
5 days interval between courses. After two courses of 
treatment, clinical observations were done on the 
therapeutic effect, and changes in hemorrheology, 
IL-6, TXB2, and 6-keto-PGF1α.   
Observation indexes and methods 
5 ml of fasting venous blood was drawn from each of 
the patients for hemorheological detection 
respectively before and after the treatment. The 
detection indexes included whole blood viscosity (at 
shear rate of 120s-1 and shear rate of 10s-1), plasma 
viscosity, hematocrit, erythrocyte deformability rate, 
and erythrocyte aggregation rate. All the detections 
were done under constant temperature.  
For IL-6 determination, all patients had 3 ml venous 
blood collected in the fasting state respectively before 
treatment, at the early stage of treatment (one week 
after treatment) and at the remission stage (30 – 35 
days after treatment). The prepared serum samples 
were kept in the refrigerator at -20ć to be detected. 
The reagent kit for IL-6 determination was from 
Scientific and Technical Development Center of the 
General Hospital of PLA.  
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For determinations of TXB2 and 6-keto-PGF1α, 5 ml 
of fasting venous blood was drawn from each of the 
patients through swift venipuncture by a 5 ml 
disposable syringe with about 0.1 ml of indomethacin 
and sodium ethylene diamine tetracetate respectively 
before treatment, at the early stage of treatment and 
at the remission stage. The blood was homogeneously 
mixed in the syringe, injected into the test-tube, and 
then centrifugated at 3500 rpm for 15 minutes at 4ć. 
The prepared plasma samples were put in the 
refrigerator at -20ć to be detected. The radio 
immunoassay kits for TXB2 and 6-keto-PGF1α were 
respectively from Beijing Yasheng Institute of 
Biological Technique and Beijing Meidikesheng 
Biological Technique Ltd.  
Statistical methods 
Chi-square test was adopted for the intergroup 
comparison of clinical therapeutic effect. Student’s t
test was adopted for comparison of changes in blood 
rheology before and after treatment, and changes in 
IL-6, TXB2, and 6-keto-PGF1α before treatment, at 
the early stage of treatment and at the remission 
stage.  
RESULTS 
The criteria for clinical therapeutic effect were drawn 
up based on the Evaluation Criteria for the Damage 
of Clinical Nervous Function of Cerebral Apoplexy 
Patients. 4 Basically cured: the score of functional 
damage decreased by 91% – 100%, the degree of 
disablement was grade 0. Markedly relieved: the 
score of functional damage decreased by 46% – 90%, 
the degree of disablement was grade 1 – 3. Improved: 
the score of functional damage decreased by 18% – 
45%. Failed: the score of function damage decreased 
by 17% or less.  
Comparison of the total effective rate among the 
three groups: Table 1. shows that the total effective 
rate of MNEFMSA group was significantly superior 
to that of the drug group (P<0.01), and the basic cure 
rate and the marked relief rate were significantly 
superior to those of the drug group and affected- 
channel group (P<0.05 or P<0.01), suggesting that 
MNEFMSA can markedly raise the clinical 
therapeutic effect for acute ischemic cerebrovascular 
diseases, and the fewer points selected can reduce the 
patient’s sufferings. 
Table 1. Comparison of the total effective rate among the three groups (Cases %) 
Group n Basically Cured Markedly Improved Improved Failed Total
Drug 30 5 (16.67) 3 (10.00) 14 (46.67) 8 (26.67) 22 (73.33)
Channel 30 9 (30.00) 7 (23.33) 11 (36.67) 3 (10.00) 27 (90.00)
MNEFMSA 30 16 (53.33) 9 (30.00)  4 (13.33) 1 (3.33) 29 (96.67)
Comparison of changes in hemorrheology of the 
three groups: Table 2. shows that before treatment, 
the hemorrheology of the three groups were abnormal, 
and after treatment, the various indexes were all 
markedly improved (P<0.05 or P<0.01), of which 
whole-blood viscosity and erythrocyte deformability 
rate of MNEFMSA group got the most obvious 
improvement, significantly different from the other 
two groups (P<0.05), suggesting that MNEFMSA 
group has a better effect than the other two groups in 
improving hemorrheology, especially in the micro- 
vessels. 
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Table 2. Comparison of hemorrheology before and after treatment among the three groups( x ±s) 
Group Time n Whole bl. vis. (high)
(mPa.s) 
Whole bl.. vis. (low)
(mPa.s) 
Plasma vis. 
(mPa.s) 
Hematocrit 
(%) 
EGR 
(%) 
EDR 
(%) 
Bef. 
Treat.
30 5.326±0.443 11.764±2.087 1.516±0.175 51.428±5.252 52.553±7.006 49.097±4.854 Drug 
Aft. 
Treat.
30 5.014±0.601*∆ 10.753±1.538*∆ 1.394±0.184* 47.436±4.113** 47.892±5.694** 51.438±4.162*∆
Bef. 
Treat.
30 5.217±0.562 11.984±1.841 1.547±0.158 52.247±5.195 53.143±6.938 49.226±4.657 Channel 
Aft. 
Treat.
30 4.873±0.674* 10.674±1.372**∆ 1.412±0.196** 48.241±4.527** 48.219±5.835** 52.107±4.076* 
Bef. 
Treat
30 5.338±0.487 11.856±1.630 1.523±0.182 51.746±5.418 51.887±7.221 49.193±4.268 MNEFMSA
Aft. 
Treat.
30 4.672±0.596** 9.872±1.442** 1.378±0.211** 47.973±4.292** 47.342±5.304** 53.384±3.237**
Note: Intragroup comparison before and after treatment, *P<0.05, **P<0.01; Compared with MNEFMSA group after treatment, 
∆P<0.05. EGR denoting erythrocyte aggregation rate and EDR erythrocyte deformability rate.                
Comparison of TXB2, 6-keto-PGF1α, and IL-6: Table 
3. shows that the three groups all got significant 
improvement in TXB2, 6-keto-PGF1α, and IL-6 levels 
at the remission stage as compared with that before 
treatment (P<0.05 or P<0.01). MNEFMSA group got 
significant improvement in 6-keto-PGF1α and IL-6 
levels ever since the early stage of treatment (P<0.05), 
suggesting that MNEFMSA can improve the level of 
IL-6 in the patients, especially at the early stage of 
treatment, it can help reduce inflammatory and 
immune reactions and lower the degree of damage to 
nervous functions so as to promote the recovery of 
disease, and also decrease effectively TXB2 but 
increase 6-keto-PGF1α.  
Table 3. Comparison of TXB2, 6-keto-PGF1α, IL-6 of patients among the three groups before treatment,  
at the early stage of treatment and at the remission stage (pg/ml, x ±s) 
Group Time n TXB2 6-keto-PGF1α IL-6 
Drug Bef. Treat. 30  345.61±261.66 31.45±13.96  207.43±103.93 
 Early Stage 30 266.97±179.27 37.81±16.78 168.03±79.78 
 Remission 30   204.06±140.80*   74.02±38.32**   111.05±28.24**
Channel Bef. Treat. 30 337.55±233.23 33.38±19.50  205.29±104.26 
 Early Stage 30  274.15±191.49 38.75±13.19 164.19±76.35 
 Remission 30   179.85±114.19**   79.46±32.47**   107.84±25.57**
MNEFMSA Bef. Treat. 30 365.95±286.59 32.55±16.12  208.23±106.08 
 Early Stage 30 266.70±177.05  42.16±13.40*  157.83±71.19* 
 Remission 30  151.93±88.23**   87.16±32.27**    93.65±16.78**
             Note: Intragroup comparison, *P<0.05, **P<0.01.  
DISCUSSION
MNEFMSA is an ancient acupuncture method by 
matching heavenly stems with viscera to treat 
diseases. The midnight-noon ebb-flow theory holds 
that when the point is open, qi and blood will pour 
into it, making it hyperactive in action, the 
acupuncture given at this hour can get twice double 
the effect. Based on the rhythmic character of the 
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attacking time of ischemic cerebrovascular diseases, 
MNEFMSA is adopted for treatment at the 
corresponding open points during the period from 7 
am. to 9 am., which is the opening hour of Stomach 
Channel of Foot Yangming. Miraculous Pivot • 
Meridians (♉ᵶ㒣•㒣㛝) states, “Foot Yangming 
Channel dominates the diseases of blood.” Yangming 
Channel is full of qi and blood. Acupuncture 
treatment given at the open hour can activate the 
channel-qi and dredge the channels and collaterals to 
replenish qi and blood, promote blood circulation by 
removing blood stasis and regulate yin and yang, thus 
the marked therapeutic effect is obtained.  
Relevant studies have suggested that the abnormal 
changes in hemorrheology play a very important part 
in the whole course of the development of 
cerebrovascular diseases, 7 and cerebral ischemia is 
also closely related with inflammatory cell factors. 8
This study also shows that patients with acute 
ischemic cerebrovascular diseases have abnormal 
level of IL-6, and those with severer damage of 
nervous function would have higher level of IL-6 
than those with milder damage, suggesting that IL-6 
is involved in the occurrence and development of 
ischemic cerebral diseases and is one of the indexes 
of damage to the cerebral nervous cells. MNEFMSA 
can help improve abnormal changes of hemo- 
rrheology, lower blood viscosity, decrease thrombosis, 
raise erythrocyte deformability rate, and as well 
markedly improve IL-6 level, promote cerebral 
circulation, increase cerebral volume of blood flow, 
raise the effective infusion of blood to cerebral 
tissues, directly improve pathological and 
physiological changes caused by cerebral ischemia 
and hypoxia, effectively protect the damaged cerebral 
tissues, and benefit the recovery of cerebral tissues. 
The improved level of IL-6 at the early stage of 
treatment may be significant for improving cerebral 
damage and decreasing inflammatory and immune 
reactions. Decreasing the content of TXB2 and 
increasing the content of 6-keto-PGF1α, especially at 
the early stage of treatment, to restore the dynamic 
equilibrium between the two can inhibit gathering of 
platelet to reduce viscosity of blood, therefore make 
cerebral vessels expand, lower vascular resistance, 
improve cerebral blood circulation, increase cerebral 
blood supply, eliminate cerebral edema, strengthen 
cerebral infusion, and improve the function of the 
affected cerebral tissues, hence the marked 
therapeutic effect is achieved, with a better recovery 
from AICD.   
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